Tennessee’s FAIR Rx Act (SB 2040 / HB 1959): Reform or Risk for Pharmacy Access?
This isn't complicated—it's willpower.
In early 2026, the Tennessee State Capitol has become the front line of a fierce battle over the future of how people get their medicine. At the center are Senator Bobby Harshbarger and Representative Rick Scarbrough, the primary sponsors of the FAIR Rx Act (SB 2040 / HB 1959).
The bill essentially tells large healthcare corporations:
You can be the insurance middleman, or you can be the pharmacy, but you can’t be both.
The legislation targets pharmacy benefit managers (PBMs) that also own retail pharmacies. Under the proposal, companies would be prohibited from owning both businesses at the same time in Tennessee, forcing them to separate those operations if the law passes.
But the political support behind the bill has also drawn attention. Several lawmakers backing the legislation have backgrounds in pharmacy or ties to the pharmacy industry, and pharmacy advocacy groups have been actively pushing for the reform. Their position is that PBM-owned pharmacies create an uneven playing field that harms independent pharmacies.
Critics, however, warn the legislation could create new problems instead of solving existing ones. Business groups such as the Tennessee Chamber of Commerce have argued that the bill interferes with free-market practices and could increase costs or reduce pharmacy access.
There is also concern about how companies might respond. Some industry voices have warned that major chains could restructure or even shut down stores in the state rather than separate their business units, potentially affecting jobs and patient access to medications.
As the debate continues, the future of SB 2040 / HB 1959 remains uncertain. What is clear is that the bill has become a flashpoint in a much larger national debate about pharmacy regulation, PBMs, drug pricing, and the structure of the healthcare industry.
If the bill passes, it could significantly reshape Tennessee’s pharmacy landscape — raising a big question for patients and workers alike:
Will this create a fairer pharmacy market, or will it unintentionally reduce access to care?
This isn't complicated—it's willpower.
In early 2026, the Tennessee State Capitol has become the front line of a fierce battle over the future of how people get their medicine. At the center are Senator Bobby Harshbarger and Representative Rick Scarbrough, the primary sponsors of the FAIR Rx Act (SB 2040 / HB 1959).
The bill essentially tells large healthcare corporations:
You can be the insurance middleman, or you can be the pharmacy, but you can’t be both.
The legislation targets pharmacy benefit managers (PBMs) that also own retail pharmacies. Under the proposal, companies would be prohibited from owning both businesses at the same time in Tennessee, forcing them to separate those operations if the law passes.
But the political support behind the bill has also drawn attention. Several lawmakers backing the legislation have backgrounds in pharmacy or ties to the pharmacy industry, and pharmacy advocacy groups have been actively pushing for the reform. Their position is that PBM-owned pharmacies create an uneven playing field that harms independent pharmacies.
Critics, however, warn the legislation could create new problems instead of solving existing ones. Business groups such as the Tennessee Chamber of Commerce have argued that the bill interferes with free-market practices and could increase costs or reduce pharmacy access.
There is also concern about how companies might respond. Some industry voices have warned that major chains could restructure or even shut down stores in the state rather than separate their business units, potentially affecting jobs and patient access to medications.
As the debate continues, the future of SB 2040 / HB 1959 remains uncertain. What is clear is that the bill has become a flashpoint in a much larger national debate about pharmacy regulation, PBMs, drug pricing, and the structure of the healthcare industry.
If the bill passes, it could significantly reshape Tennessee’s pharmacy landscape — raising a big question for patients and workers alike:
Will this create a fairer pharmacy market, or will it unintentionally reduce access to care?
Tennessee’s FAIR Rx Act (SB 2040 / HB 1959): Reform or Risk for Pharmacy Access?
This isn't complicated—it's willpower.
In early 2026, the Tennessee State Capitol has become the front line of a fierce battle over the future of how people get their medicine. At the center are Senator Bobby Harshbarger and Representative Rick Scarbrough, the primary sponsors of the FAIR Rx Act (SB 2040 / HB 1959).
The bill essentially tells large healthcare corporations:
You can be the insurance middleman, or you can be the pharmacy, but you can’t be both.
The legislation targets pharmacy benefit managers (PBMs) that also own retail pharmacies. Under the proposal, companies would be prohibited from owning both businesses at the same time in Tennessee, forcing them to separate those operations if the law passes.
But the political support behind the bill has also drawn attention. Several lawmakers backing the legislation have backgrounds in pharmacy or ties to the pharmacy industry, and pharmacy advocacy groups have been actively pushing for the reform. Their position is that PBM-owned pharmacies create an uneven playing field that harms independent pharmacies.
Critics, however, warn the legislation could create new problems instead of solving existing ones. Business groups such as the Tennessee Chamber of Commerce have argued that the bill interferes with free-market practices and could increase costs or reduce pharmacy access.
There is also concern about how companies might respond. Some industry voices have warned that major chains could restructure or even shut down stores in the state rather than separate their business units, potentially affecting jobs and patient access to medications.
As the debate continues, the future of SB 2040 / HB 1959 remains uncertain. What is clear is that the bill has become a flashpoint in a much larger national debate about pharmacy regulation, PBMs, drug pricing, and the structure of the healthcare industry.
If the bill passes, it could significantly reshape Tennessee’s pharmacy landscape — raising a big question for patients and workers alike:
Will this create a fairer pharmacy market, or will it unintentionally reduce access to care?
